Cargando…

Clinical-Pathological Characteristics and Prognosis of a Cohort of Oesophageal Cancer Patients: a Competing Risks Survival Analysis

BACKGROUND: To determine the clinical course, follow-up strategies, and survival of oesophageal cancer patients using a competing risks survival analysis. METHODS: We conducted a retrospective and prospective follow-up study. The study included 180 patients with a pathological diagnosis of oesophage...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Camacho, Elena, Pita-Fernández, Salvador, Pértega-Díaz, Sonia, López-Calviño, Beatriz, Seoane-Pillado, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Epidemiological Association 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341000/
https://www.ncbi.nlm.nih.gov/pubmed/25716135
http://dx.doi.org/10.2188/jea.JE20140118
Descripción
Sumario:BACKGROUND: To determine the clinical course, follow-up strategies, and survival of oesophageal cancer patients using a competing risks survival analysis. METHODS: We conducted a retrospective and prospective follow-up study. The study included 180 patients with a pathological diagnosis of oesophageal cancer in A Coruña, Spain, between 2003 and 2008. The Kaplan-Meier methodology and competing risks survival analysis were used to calculate the specific survival rate. The study was approved by the Ethics Review Board (code 2011/372, CEIC Galicia). RESULTS: The specific survival rate at the first, third, and fifth years was 40.2%, 18.1%, and 12.4%, respectively. Using the Kaplan-Meier methodology, the survival rate was slightly higher after the third year of follow-up. In the multivariate analysis, poor prognosis factors were female sex (hazard ratio [HR] 1.94; 95% confidence interval [CI], 1.24–3.03), Charlson’s comorbidity index (HR 1.17; 95% CI, 1.02–1.33), and stage IV tumours (HR 1.70; 95% CI, 1.11–2.59). The probability of dying decreased with surgical and oncological treatment (chemotherapy and/or radiotherapy) (HR 0.23; 95% CI, 0.12–0.45). The number of hospital consultations per year during the follow-up period, from diagnosis to the appearance of a new event (local recurrences, newly appeared metastasis, and newly appeared neoplasias) did not affect the probability of survival (HR 1.03; 95% CI, 0.92–1.15). CONCLUSIONS: The Kaplan-Meier methodology overestimates the survival rate in comparison to competing risks analysis. The variables associated with a poor prognosis are female sex, Charlson’s comorbidity score and extensive tumour invasion. Type of follow-up strategy employed after diagnosis does not affect the prognosis of the disease.